Overexpression of ErbB2 is found in several types of human carcinomas. In breast tumors, ErbB2 overexpression is detected in up to 20% of patients. Breast cancers in with amplification of ErbB2 are characterized by rapid tumor growth, lower survival rate and increased disease progression. The molecular mechanisms underlying the oncogenic action of ErbB2 involve a complex signaling network that tightly regulates malignant cell migration and invasion and hence metastatic potential. Recent efforts have been made to identify gene expression signatures of ErbB2-positive invasive breast cancers that may represent important mediators of ErbB2-induced tumorigenesis and metastatic progression. In this chapter, we will discuss the canonical ErbB2 signaling pathways responsible for tumor growth and dissemination along with newly identified mediators such as adaptor protein p130Cas and miRNAs. From a therapeutic point of view, the treatment with anti-ErbB2 monoclonal antibody trastuzumab has greatly improved the outcomes of patients with ErbB2 aggressive cancer. Nevertheless, de novo and acquired resistance to trastuzumab therapy still represent a major clinical problem. In the second part of the chapter, we will provide an overview of the mechanisms so far implicated in the onset of resistance to targeted therapy and of the new strategies to overcome resistance.
- breast cancer
- molecular mechanisms
Breast cancer is the leading cause of cancer-related death in women worldwide . Despite significant advances in breast cancer diagnosis and treatment, several major unresolved clinical and scientific problems still remain, such as the understanding of the causes of tumor progression and resistance and how to predict them.
ErbB2 is a well-known oncoprotein that belongs to the epidermal growth factor receptor epidermal growth factor receptor (EGFR) family. It is overexpressed approximately in 20% of invasive breast cancers . In particular, overexpression of ErbB2 has been demonstrated to promote breast cancer invasion and metastasis and to correlate with poor patient survival [3–6]. ErbB2 is also overexpressed in noninvasive mammary ductal carcinomas
The identification of the deregulated ErbB2 pathway in breast cancer pathogenesis has led to the development of ErbB2-targeted therapies. Although ErbB2 overexpression identifies patients who are likely to respond to therapy with trastuzumab, not all patients benefit from treatment. To date, approximately 15% of patients relapse after therapy due to
2. Molecular mechanisms of ErbB2 activation
Downstream signaling pathways are activated upon ErbB2 receptor activation through either heterodimerization with ligand bound EGFR, ErbB3, or ErbB4 family receptors, or in presence of overexpression of ErbB2 due to gene amplification, by ligand independent homodimerization . The homo/heterodimerization promotes the receptor activation that in turn leads to tyrosine phosphorylation of the C-terminal residues. Numerous phosphorylation sites exist within the cytoplasmic domain of ErbB2, these sites are essential for protein-protein interactions and induction of the signaling cascades downstream to ErbB2 receptor activation. To this regard, the activation of the phosphoinositide 3-kinase (PI3K) and Ras/RAF/MEK/ERK1/2 pathways are hallmarks of ErbB2 activation.
Besides the canonical interaction with the member of the ErbB family, it has been recently demonstrated that activation of ErbB2 can be induced through its interaction with additional transmembrane partners. Among them Mucin 1 that is overexpressed in breast cancer and has been shown to interact with EGFR and ErbB2 leading to activation of PI3K and MAPKs pathways . In addition, it has been demonstrated that leptin receptor upon leptin binding can phosphorylate and activate ErbB2 contributing to activation of mitogen-activated protein kinase 1 (MAPK) activity . It is worth noting that further amplification of the ErbB2 signaling may derive from its crosstalk with other signaling mediators. For instance, it has been demonstrated that ErbB2 can cross-talk with hormone receptors, insulin growth factor receptor (IGFR), protein phosphatases, transforming growth beta receptor (TGFR-beta) and ion channels resulting in a complex signaling network that contribute to tumor growth and progression .
2.1. Canonical ErbB2 signaling network
Several downstream signaling pathways are activated after ErbB2 receptor activation leading to the regulation of cell proliferation, growth and survival as well as invasion and angiogenesis . Tyrosine residues phosphorylation resulting from receptor activation can recruit a variety of intracellular adaptor and scaffold proteins that in turn mediate the activation of downstream signaling pathways.
One of the most important pathways activated by ErbB2 signaling is the RAS-MAPK pathway . The activation of the MAPK pathway controls cell proliferation, survival and migration and alteration of this pathway have been linked with many diseases including cancer.
Upon ErbB2 activation, the adaptor molecule growth factor receptor-bound protein 2 (GRB2) binds through its SH2 domain to the phosphorylated intracellular tail of ErbB2. GRB2 bound to the receptor recruits the adaptor protein son of sevenless (SOS) determining its activation. Active SOS can trigger the activation of RAS by inducing the transition the GDP-inactive to the GTP-active state. The activation of RAS promotes a cascade of downstream kinase activation that ultimately leads to the phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK1, ERK2) [17, 18]. Activated ERK proteins phosphorylate a number of transcription factors such as Elk-1, c-Fos and c-Jun among others, that regulate the expression of genes implicated in cell growth, differentiation, proliferation, survival and migration [15, 19].
The PI3K/AKT is the second canonic pathway activated by ErbB2 and due to its relevance in cell proliferation, survival, protein synthesis, invasion and drug resistance has received much attention to develop anticancer targeted therapy [17, 18, 20]. Upon receptor activation, the p85 subunit of PI3K binds to tyrosine-phosphorylated residues of ErbB2. This recruitment determines the release of the 110 subunit of PI3K and allows the formation of PI3K heterodimers that can phosphorylate PIP2 substrate in PIP3 . Ultimately PIP3 promotes the localization of AKT at cell membrane and its phosphorylation by PDK1 and mTOR complex 2. AKT represents the major effector of the PI3K/AKT signaling pathway leading to the regulation of many cell functions such as cell survival, cell growth and proliferation  (Figure 1).
2.2. ErbB2 signaling mediated by the adaptor proteins p130Cas
It is clear that activation of canonical ErbB2 signaling can be achieved through the recruitment of signaling proteins to the receptor. It is now emerging that p130Cas adaptor protein can mediate the activation of ErbB2 downstream signaling pathways. p130Cas/BCAR1 scaffold molecule is a signaling molecule involved in the linkage of actin cytoskeleton to the extracellular matrix during cell migration, cell invasion and cell transformation [22, 23] and it has been described as an essential transducer element in ErbB2 transformation and progression . Due to its modular structure, p130Cas has been described to play a crucial role in signaling originating from many amplified or mutated oncogenes, by undergoing hyperphosphorylation and association with multiple signaling partners required for transformation .
It was recently demonstrated that overexpression of p130Cas in ErbB2 breast cancers correlates with poor survival and increased progression. In particular, p130Cas is required for ErbB2-dependent transformation and invasion both
2.3. MicroRNA in ErbB2-overexpressing cancer
The discovery of microRNAs (miRNAs) has provided new perspectives to study cancer at the molecular level. These noncoding regulatory RNA molecules of ~22 nucleotides have emerged as important cancer biomarkers, effectors and targets. Alteration of miRNAs expression has been correlated with a variety of human diseases, including breast cancer .
It was initially demonstrated that the overexpression of miR-125a and miR-125b in human breast cancer cell line SKBR3 overexpressing ErbB2 was sufficient to lower ErbB2 and ErbB3 mRNA and protein levels, with consequent inhibition of anchorage-dependent growth, migration and invasion. Consistently, activation of canonical ErbB2 downstream signaling such as MAPK and PI3K/Akt pathways was severely impaired . Two subsequent studies identified by using different methodologies two miRNA signatures of ErbB2 positive breast cancer. In particular, miR-520d, miR-181c, miR-302c, miR-376b, miR-30e were identified as miRNA associated with HER2 status to be added to the previously found let-7f, let-7g, miR-107, mir-10b, miR-126, miR-154 and miR-195 as miRNA characterizing HER2 status [29, 30]
These data highlight the relevance of microRNA signatures as novel breast cancer biomarkers. The consequences of the association of ErbB2 and miRNAs are still under investigation but three possible scenarios can be identified. The first one envisages the regulation of miRNAs as a consequence of ErbB2 activation. The second possibility is that miRNAs contributes to the activation of ErbB2 and to its capacity to trigger downstream-signaling pathways. The last option is that miRNAs can interfere with the response to ErbB2 targeted-therapy thereby mediating the onset of resistance.
Further investigations are needed to identify which is the crucial miRNAs implicating in the different responses to ErbB2 activation and to develop new selective anticancer therapy.
3. Role of Erbb2 in breast cancer invasion and metastasis
From the physiological point of view, ErbB2 represents an important molecule implicated in the regulation of cell proliferation, differentiation, survival and migration during embryonic development and in adults, during tissue maintenance. Importantly, during pathological conditions, ErbB2 aberrant expression and activation in breast cancer have been extensively linked to invasive, aggressive phenotype and poor prognosis . Acquirement of migratory properties allow cancer cell to invade the surrounding tissues and reach the blood vessels to generate metastasis. At the cellular level, the transition from noninvasive to invasive status is characterized by loss of the epithelial characteristics such as expression of cytokeratins and E-cadherin and gain of mesenchymal traits like vimentin, fibronectin and N-cadherin through a process that is known as epithelial to mesenchymal transition (EMT) . EMT promotes cancer progression by allowing cancer cells to acquire invasive properties, to metastasize and also to acquire stem cell properties [33, 34]. Interestingly, these cells that have acquired stem cell properties are characterized by increased expression of EMT genes, such as FoxC2, Zeb and N-cadherin [35, 36]. Moreover, it has been demonstrated that ErbB2 overexpression in breast cancer cell lines can enhance the stem cell population which is responsible for breast cancer progression .
3.1. Erbb2 invasive signaling signature
For the past years, extensive investigations have been performed in order to understand the precise mechanisms implicated in the regulation of cell invasion and metastasis as the result of ErbB2 activation. Several
The study of the consequences ErbB2/Neu activation in
4. Mechanisms of Erbb2—breast cancer therapy resistance
The assessment that ErbB2 overexpression correlates with aggressive breast cancer and poor survival has led to the development of targeted therapies to inhibit the receptor. Among them, the monoclonal antibody is trastuzumab and pertuzumab and the tyrosine kinase inhibitor is lapatinib . Although ErbB2 overexpression identifies patients who are likely to respond to targeted therapy, not all of them benefit from the treatment. Indeed, many patients relapse after therapy due to the acquirement of primary or acquired resistance. Primary resistance might occur because of lack of target dependency or activation of compensatory pathways [45, 46]. Acquired resistance, which develops in most patients with advanced disease, may be due to the loss of the expression of the target because of continuous therapy, or to additional mutations that occur either in the target or on downstream signaling pathways that ultimately result in enhanced cell proliferation .
Many factors can contribute to resistance to ErbB2-targeted therapies. Among them, loss of ErbB2 amplification, compensatory mechanisms such as ErbB3 activation or the presence of p95ErbB2, a fragment of ErbB2 that cannot bind to trastuzumab as it lacks the extracellular part but can still activate the downstream pathways by retaining the ability to associate with ErbB2-signaling partners . Additional factors that might be responsible for resistance to ErbB2-targeted therapies include aberrant activation of downstream signaling pathways due to mutations occurring during therapy, for example in the PI3K pathway [48, 49] or the activation of crosstalk with other receptor tyrosine kinases leading to compensatory mechanisms [50, 51].
In addition, poor internalization of ErbB2 resulting in a long half-life at the plasma membrane has been described as an important mechanism implicated in ErbB2 therapy resistance. In this context, it has been shown that Hsp90 inhibition can induce ErbB2 ubiquitination followed by its downregulation , however the mechanisms underlying ErbB2 downregulation are still obscure. Recently it has been demonstrated that molecular association between p130Cas and ErbB2 protects the receptor from degradation through autophagy . On this regard, increasing evidence points out that ubiquitination is an important mechanism driving autophagic degradation. Interestingly, in breast cancer cells overexpressing ErbB2, p130Cas protects ErbB2 from autophagy-mediated degradation by interfering with its ubiquitination, thus suggesting that high levels of p130Cas expression might be crucial to promote resistance to trastuzumab treatment by protecting ErbB2 from degradation .
In conclusion, the unraveling of the molecular mechanisms responsible for resistance would greatly contribute to improve prognosis and outcomes for patients with ErbB2 tumors allowing a better selection of patients who are likely to respond to ErbB2-targeted therapies. Moreover, the dissection of the molecular pathways might reveal new insights for the development of strategies to overcome resistance.
4.1. Overcoming resistance to targeted therapy
Two main strategies have been adopted to try to overcome resistance to trastuzumab therapy. One strategy is still based on targeting ErbB2 either by maintaining trastuzumab therapy beyond progression, since it has been demonstrated that some patients could benefit of trastuzumab therapy with progressive disease [54, 55], or by treatment with TKI inhibitor lapatinib in combination with chemotherapy . Another option is to treat trastuzumab resistant patients with the T-DM1. T-DM1 consists of an antibody (trastuzumab) conjugated with a microtubule inhibitor (maytansine derivative) with cytotoxic activity (developed by Genentech, Inc.).
At present, many new drugs targeting ErbB2 are undergoing clinical investigation in patients with ErbB2-resistant breast cancer overexpression. Since resistance to ErbB2-targeted therapy might occur as a result of aberrant activation of signaling pathways downstream to the receptor, the other strategy adopted to overcome resistance to trastuzumab is to target downstream signaling pathways known to be activated by ErbB2.
A major effort has been undertaken to inhibit the PI3K/Akt/mTOR pathway that, as mentioned before, is one of the most relevant downstream signaling activated by ErbB2. Indeed, alterations of PI3K/Akt pathway result in the upregulation of the mTOR pathway that in turn promotes translation and increased cellular proliferation [57, 58]. These signaling events have been characterized in breast cancer models in which the PI3K/Akt/mTOR axis is constitutively activated and responsible for the acquirement of resistance to ErbB2-targeted therapy . It has been also described that the deregulation of this pathway accounts for gain of function mutations
Further ongoing characterization of the key effectors implicated in the resistance of ErbB2-targeted therapy might provide new efficacious pharmaceutics to improve or to overcome trastuzumab resistance.
Many progresses have been made in the understanding of the molecular mechanisms leading to the activation of ErbB2 and its downstream signaling pathways. Further studies are needed for a better comprehension of the mechanisms that lead to resistance to ErbB2-targeted treatment and especially to identify the crucial molecules deserving a therapeutic approach. New efforts have to be undertaken to see whether new modulators of ErbB2 such as miRNAs and adaptor proteins like p130Cas can be used as new therapeutic targets.
Research support to Sara Cabodi from AIRC IG11346, MIUR (FIRB giovani 2008 RBFR08F2FS) and Ricerca Sanitaria Finalizzata GR-20091543842. Maria del Pilar Camacho Leal is supported by an Umberto Veronesi Foundation Fellowship.
Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol2006, 24(14):2137–2150.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science1989, 244(4905):707–712.
Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y:Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle2012, 11(13):2486–2494.
Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell2002, 2(6):451–461.
Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, Koromilas AE: Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle2011, 10(5):794–804.
Tan M, Yao J, Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res1997, 57(6):1199–1205.
Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C: The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene1992, 7(5):1027–1032.
Feigin ME, Muthuswamy SK: ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res2009, 315(4):707–716.
Baselga J: Treatment of HER2-overexpressing breast cancer. Ann Oncol2010, 21 Suppl 7:vii36–40.
Emde A, Kostler WJ, Yarden Y: Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol2012, 84 Suppl 1:e49–57.
Valabrega G, Montemurro F, Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol2007, 18(6):977–984.
Schulz R, Streller F, Scheel AH, Ruschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM: HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis2014, 5:e980.
Kufe DW: MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene2013, 32(9):1073–1081.
Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, Herman B, Gertler A: Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett2004, 565(1–3):139–142.
Dittrich A, Gautrey H, Browell D, Tyson-Capper A: The HER2 signaling network in breast cancer--like a spider in its web. J Mammary Gland Biol Neoplasia2014, 19(3–4):253–270.
Lemmon MA, Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell2010, 141(7):1117–1134.
Aksamitiene E, Kiyatkin A, Kholodenko BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans2012, 40(1):139–146.
De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signaling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets2012, 16 Suppl 2:S17–27.
Romeo Y, Zhang X, Roux PP: Regulation and function of the RSK family of protein kinases. Biochem J2012, 441(2):553–569.
Fruman DA, Rommel C: PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov2014, 13(2):140–156.
Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM: The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev2010, 29(4):751–759.
Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P: Integrin signaling adaptors: not only figurants in the cancer story. Nat Rev Cancer2010, 10(12):858–870.
Defilippi P, Di Stefano P, Cabodi S: p130Cas: a versatile scaffold in signaling networks. TrenWds Cell Biol2006, 16(5):257–263.
Cabodi S, Tinnirello A, Bisaro B, Tornillo G, del Pilar Camacho-Leal M, Forni G, Cojoca R, Iezzi M, Amici A, Montani M et al: p130Cas is an essential transducer element in ErbB2 transformation. FASEB J2010, 24(10):3796–3808.
Tornillo G, Bisaro B, Camacho-Leal Mdel P, Galie M, Provero P, Di Stefano P, Turco E, Defilippi P, Cabodi S: p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1. Eur J Cell Biol2011, 90(2–3):237–248.
Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G et al: p130Cas as a new regulator of mammary epithelial cell proliferation, survival and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res2006, 66(9):4672–4680.
Wang SE, Lin RJ: MicroRNA and HER2-overexpressing cancer. Microrna2013, 2(2):137–147.
Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem2007, 282(2):1479–1486.
Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G et al.: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res2009, 11(3):R27.
Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer2006, 5:24.
Brix DM, Clemmensen KK, Kallunki T: When good turns bad: regulation of invasion and metastasis by ErbB2 receptor tyrosine kinase. Cells2014, 3(1):53–78.
Lamouille S, Xu J, Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol2014, 15(3):178–196.
Appert-Collin A, Hubert P, Cremel G, Bennasroune A: Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol2015, 6:283.
Mallini P, Lennard T, Kirby J, Meeson A: Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev2014, 40(3):341–348.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A2009, 106(33):13820–13825.
Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One2008, 3(8):e2888.
Korkaya H, Paulson A, Iovino F, Wicha MS: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene2008, 27(47):6120–6130.
Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL: HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res2006, 66(19):9591–9600.
Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy SK, Chernoff J: A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene2010, 29(43):5839–5849.
Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, Valo E, Fehrenbacher N, Olsen CJ, Daugaard M, Egebjerg C et al.: ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell2012, 45(6):764–776.
Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS: ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol2001, 3(9):785–792.
Pincini A, Tornillo G, Orso F, Sciortino M, Bisaro B, Leal Mdel P, Lembo A, Brizzi MF, Turco E, De Pitta C et al.: Identification of p130Cas/ErbB2-dependent invasive signatures in transformed mammary epithelial cells. Cell Cycle2013, 12(15):2409–2422.
Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ: Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer2007, 7(5):389–397.
Wilks ST: Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. Breast2015, 24(5):548–555.
Higgins MJ, Baselga J: Targeted therapies for breast cancer. J Clin Invest2011, 121(10):3797–3803.
Rexer BN, Arteaga CL: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog2012, 17(1):1–16.
Hurvitz SA, Hu Y, O'Brien N, Finn RS: Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev2013, 39(3):219–229.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M et al.: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell2007, 12(4):395–402.
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res2008, 68(22):9221–9230.
Bender LM, Nahta R: Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci2008, 13:3906–3912.
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res2005, 65(23):11118–11128.
Bertelsen V, Stang E: The mysterious ways of ErbB2/HER2 trafficking. Membranes (Basel)2014, 4(3):424–446.
Bisaro B, Sciortino M, Colombo S, Camacho Leal MP, Costamagna A, Castellano I, Montemurro F, Rossi V, Valabrega G, Turco E et al.: p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. Oncotarget2016, 7(4):4442–4453.
Mannocci A, De Feo E, de Waure C, Specchia ML, Gualano MR, Barone C, Ricciardi W, La Torre G: Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies. Tumori2010, 96(3):385–391.
Petrelli F, Barni S: A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer2013, 13(2):81–87.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med2006, 355(26):2733–2743.
Burris HA, 3rd: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol2013, 71(4):829–842.
Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol2009, 2:45.
Keck S, Glencer AC, Rugo HS: Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncol2012, 8(11):1383–1396.
Mayer I: Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol2013, 11(4):217–224.
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther2010, 9(6):1489–1502.
Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol2010, 21(2):255–262.
Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL: Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res2014, 16(1):R9.
Whenham N, D'Hondt V, Piccart MJ: HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer2008, 8(1):38–49.
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A et al: Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res2009, 15(23):7266–7276.
Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA: Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol2010, 28(34):5110–5115.
Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E et al: A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat2013, 141(3):437–446.
Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L: Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat2011, 125(2):447–455.
Brufsky AM: Current approaches and emerging directions in HER2-resistant breast cancer. Breast Cancer (Auckl)2014, 8:109–118.